An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission.

The EU has approved an injectable HIV drug offering a two-month dosage schedule, marking a breakthrough in treatment ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as one of the important intervention strategies for high-risk populations in the ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.